PTC Therapeutics (PTCT) Misses Q3 EPS by 22c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results 
October 27, 2022 4:03 PM EDT- Total quarterly revenue of $217 million, representing 57% year-over-year growth -- 2022 DMD revenue guidance and low end of total revenue guidance increased -- Strategic financing with Blackstone with up to $1 billion of low-cost, low-dilution capital -- Pipeline of multiple innovative compounds continues to advance in clinical development -
SOUTH PLAINFIELD, N.J., Oct. 27, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2022.Â
... More